June 13, 2012
You don’t have to be a superhero to provide effective CPR. Using a ResQPump (CardioPump), which permits the person performing CPR to decompress the chest, with a ResQPOD, an impedance threshold device, produces a combination called active compression decompression CPR (ACD CPR) that, according to a study, can increase a cardiac arrest patient’s survival rate by 53%.
Although not currently available for sale in the United States, the ResQPump utilizes a suction cup that sticks to the chest and “transfers a lifting force to the thorax,” allowing the rescuer to re-expand the chest during the decompression phase of CPR. Advanced Circulatory Systems, Inc., the manufacturer of this product, will be using the study to support their submission for FDA approval. If approved, the ResQPump should be available for sale in the United States in 2012.
The ResQPOD, which is currently available in the United States, is designed to work with an endotracheal tube (ET) or facemask and “prevents unnecessary air from entering the chest during CPR. As the chest wall recoils, the vacuum (negative pressure) in the thorax is greater. This enhanced vacuum pulls more blood back to the heart, doubling blood flow during CPR.” According to a study published in The Lancet, this mechanism increases cardiac output, blood pressure, and survival rates when used with ACD CPR.
In a recent article, Dr. Tom P. Aufderheide, a principal investigator of the study, stated, “The goal of resuscitation during cardiac arrest is long-term survival with preservation of brain function. This new, effective intervention achieves that goal and is potentially the most significant advancement in the treatment of cardiac arrest since defibrillation.”
We will have to wait and see how this new technology will impact cardiac arrest patients. What do you think about its promising benefits?